JP2025500482A5 - - Google Patents
Info
- Publication number
- JP2025500482A5 JP2025500482A5 JP2024538258A JP2024538258A JP2025500482A5 JP 2025500482 A5 JP2025500482 A5 JP 2025500482A5 JP 2024538258 A JP2024538258 A JP 2024538258A JP 2024538258 A JP2024538258 A JP 2024538258A JP 2025500482 A5 JP2025500482 A5 JP 2025500482A5
- Authority
- JP
- Japan
- Prior art keywords
- saponin
- bonds
- linker
- bond
- ligand
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| NL2030215 | 2021-12-22 | ||
| NL2030215 | 2021-12-22 | ||
| PCT/NL2022/050736 WO2023121446A1 (en) | 2021-12-22 | 2022-12-20 | Targeted saponin-nucleic acid conjugates for treatment of muscle wasting disorders |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2025500482A JP2025500482A (ja) | 2025-01-09 |
| JP2025500482A5 true JP2025500482A5 (https=) | 2025-12-26 |
Family
ID=81585344
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2024538258A Pending JP2025500482A (ja) | 2021-12-22 | 2022-12-20 | 筋消耗性障害の治療用の標的型サポニン－核酸コンジュゲート |
Country Status (11)
| Country | Link |
|---|---|
| US (1) | US20250057971A1 (https=) |
| EP (2) | EP4452331B8 (https=) |
| JP (1) | JP2025500482A (https=) |
| KR (1) | KR20240121778A (https=) |
| CN (1) | CN118414172A (https=) |
| CA (1) | CA3240612A1 (https=) |
| DK (1) | DK4452331T3 (https=) |
| ES (1) | ES3052234T3 (https=) |
| IL (1) | IL313728A (https=) |
| PT (1) | PT4452331T (https=) |
| WO (1) | WO2023121446A1 (https=) |
Families Citing this family (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| SG11202100928QA (en) | 2018-08-02 | 2021-02-25 | Dyne Therapeutics Inc | Muscle targeting complexes and uses thereof for treating facioscapulohumeral muscular dystrophy |
| US12018087B2 (en) | 2018-08-02 | 2024-06-25 | Dyne Therapeutics, Inc. | Muscle-targeting complexes comprising an anti-transferrin receptor antibody linked to an oligonucleotide and methods of delivering oligonucleotide to a subject |
| US11168141B2 (en) | 2018-08-02 | 2021-11-09 | Dyne Therapeutics, Inc. | Muscle targeting complexes and uses thereof for treating dystrophinopathies |
| CA3108282A1 (en) | 2018-08-02 | 2020-02-06 | Dyne Therapeutics, Inc. | Muscle targeting complexes and uses thereof for treating dystrophinopathies |
| US12370264B1 (en) | 2018-08-02 | 2025-07-29 | Dyne Therapeutics, Inc. | Complexes comprising an anti-transferrin receptor antibody linked to an oligonucleotide and method of delivering oligonucleotide to a subject |
| US12097263B2 (en) | 2018-08-02 | 2024-09-24 | Dyne Therapeutics, Inc. | Muscle targeting complexes and uses thereof for treating myotonic dystrophy |
| US11771776B2 (en) | 2021-07-09 | 2023-10-03 | Dyne Therapeutics, Inc. | Muscle targeting complexes and uses thereof for treating dystrophinopathies |
| US11969475B2 (en) | 2021-07-09 | 2024-04-30 | Dyne Therapeutics, Inc. | Muscle targeting complexes and uses thereof for treating facioscapulohumeral muscular dystrophy |
| IL316143A (en) | 2022-04-15 | 2024-12-01 | Dyne Therapeutics Inc | Muscle targeting complexes and formulations for the treatment of myotonic dystrophy |
| KR20260025101A (ko) * | 2023-06-02 | 2026-02-23 | 사프렘 테크놀로지스 비.브이. | 세포내 분자 표적을 통해 작용하는 치료적 이펙터 성분을 위한 개선된 치료 요법 |
Family Cites Families (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| MX9204374A (es) | 1991-07-25 | 1993-03-01 | Idec Pharma Corp | Anticuerpo recombinante y metodo para su produccion. |
| US10626395B2 (en) | 2016-10-27 | 2020-04-21 | The General Hospital Corporation | Therapeutic targeting of a microRNA to treat Duchenne muscular dystrophy |
| MX2019008199A (es) | 2017-01-06 | 2019-11-25 | Avidity Biosciences Llc | Composiciones de acido nucleico polipeptido y metodos de induccion de la omision de exon. |
| IL280536B2 (en) | 2018-08-02 | 2024-12-01 | Dyne Therapeutics Inc | Complexes targeting transferrin receptor and uses thereof |
| SG11202106603UA (en) | 2018-12-21 | 2021-07-29 | Sapreme Tech Bv | Biologically active cluster of molecules |
| CA3163283A1 (en) | 2020-01-10 | 2021-07-15 | Romesh R. Subramanian | Muscle targeting complexes and uses thereof for modulation of genes associated with muscle health |
-
2022
- 2022-12-20 US US18/723,157 patent/US20250057971A1/en active Pending
- 2022-12-20 PT PT228306213T patent/PT4452331T/pt unknown
- 2022-12-20 CN CN202280083977.7A patent/CN118414172A/zh active Pending
- 2022-12-20 DK DK22830621.3T patent/DK4452331T3/da active
- 2022-12-20 ES ES22830621T patent/ES3052234T3/es active Active
- 2022-12-20 WO PCT/NL2022/050736 patent/WO2023121446A1/en not_active Ceased
- 2022-12-20 CA CA3240612A patent/CA3240612A1/en active Pending
- 2022-12-20 KR KR1020247021690A patent/KR20240121778A/ko active Pending
- 2022-12-20 EP EP22830621.3A patent/EP4452331B8/en active Active
- 2022-12-20 JP JP2024538258A patent/JP2025500482A/ja active Pending
- 2022-12-20 IL IL313728A patent/IL313728A/en unknown
- 2022-12-20 EP EP25186753.7A patent/EP4610278A3/en active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2025500482A5 (https=) | ||
| JP2025501610A5 (https=) | ||
| ES3052234T3 (en) | Targeted saponin-nucleic acid conjugates for treatment of muscle wasting disorders | |
| JP2025500481A5 (https=) | ||
| US20250051770A1 (en) | Compositions comprising therapeutic nucleic acid and saponin for the treatment of muscle-wasting disorders | |
| US20250082759A1 (en) | Compositions comprising therapeutic nucleic acid and targeted saponin for the treatment of muscle-wasting disorders | |
| KR20250004769A (ko) | 근긴장성 이영양증을 치료하기 위한 근육 표적화 복합체 및 그의 용도 | |
| KR20250004771A (ko) | 근긴장성 이영양증을 치료하기 위한 근육 표적화 복합체의 투여 | |
| EP4355369B1 (en) | Conjugate of saponin, oligonucleotide and galnac | |
| AU2024312687A1 (en) | Conjugates of saponin and antisense oligonucleotides for use in the treatment of neurodegenerative diseases | |
| US20240327829A1 (en) | Conjugate of saponin, oligonucleotide and galnac | |
| US20250205361A1 (en) | Treatment regimens for therapeutic effector components that act via an intracellular molecular target | |
| HK40118872B (en) | Targeted saponin-nucleic acid conjugates for treatment of muscle wasting disorders | |
| HK40118872A (en) | Targeted saponin-nucleic acid conjugates for treatment of muscle wasting disorders | |
| KR20260026556A (ko) | 중추신경계 장애의 치료를 위한 약제학적 조성물 | |
| HK40124033A (en) | Conjugate of saponin, oligonucleotide and galnac | |
| HK40110483B (en) | Conjugate of saponin, oligonucleotide and galnac | |
| HK40110483A (en) | Conjugate of saponin, oligonucleotide and galnac | |
| HK40091234B (en) | Conjugate of saponin, oligonucleotide and galnac |